Itacitinib for GVHD Prevention

Single Center Pilot Study to Investigate the Efficacy of Adding Itacitinib to Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning Matched Donor Hematopoietic Cell Transplantation With Peripheral Blood Stem Cells as Graft Source

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
50 patients (estimated)
Sponsors
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Tags
Allogeneic Stem Cell Transplant, Chemotherapy, JAK1 Inhibitor, Post-Allogeneic Stem Cell Transplant
Trial Type
Supportive
Last Update
1 month ago
SparkCures ID
1652
NCT Identifier
NCT05364762

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.